EP-1013
- Product Name
- EP-1013
- CAS No.
- 223568-55-6
- Chemical Name
- EP-1013
- Synonyms
- F 1013;EP-1013;EP1013,EP-1013;EP1013 (F1013);Z-VD-FMK (mixture of isomers);(3S)-5-Fluoro-3-[[(2S)-3-methyl-1-oxo-2-[[(phenylmethoxy)carbonyl]amino]butyl]amino]-4-oxopentanoic acid;Pentanoic acid, 5-fluoro-3-[[(2S)-3-methyl-1-oxo-2-[[(phenylmethoxy)carbonyl]amino]butyl]amino]-4-oxo-, (3S)-
- CBNumber
- CB42627805
- Molecular Formula
- C18H23FN2O6
- Formula Weight
- 382.38
- MOL File
- 223568-55-6.mol
EP-1013 Property
- Boiling point:
- 639.8±55.0 °C(Predicted)
- Density
- 1.258±0.06 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- DMSO : ≥ 60 mg/mL (156.91 mM)
- pka
- 3.92±0.19(Predicted)
- form
- Solid
- color
- White to off-white
EP-1013 Chemical Properties,Usage,Production
Uses
EP1013 (F1013) is a broad-spectrum caspase selective inhibitor, used in the research of type 1 diabetes[1].
in vivo
EP1013 (1, 3, 10 mg/kg) significantly improves marginal islet mass function. Two animals in the 10 mg/kg EP1013 treatment group exhibit primary islet graft nonfunction, but the diabetes reversal rate for this group is not significantly different from the 3 mg/kg EP1013, 1 mg/kg EP1013, or 10 mg/kg zVAD groups. EP1013 therapy enhances functional syngeneic islet mass and promotes longevity of islet graft function[1].
IC 50
Caspase
References
[1] Emamaullee JA, et al. The caspase selective inhibitor EP1013 augments human islet graft function and longevity in marginal mass islet transplantation in mice. Diabetes. 2008 Jun;57(6):1556-66. DOI:10.2337/db07-1452